Stay informed
Dropdown menu

building a

solid tgct

care plan

When it comes to living with tenosynovial giant cell tumor (TGCT), you shouldn't have to endure the "bad days" alone. By partnering with the right care team, you can consider a range of treatment options for TGCT.1

Partnering with
your care team

You play a key role in developing a treatment plan that’s right for you. Share your treatment priorities—such as wanting to shrink your tumor and associated inflammation or avoid worsening symptoms—and ask any questions you have about treatment options.

Some key questions:

  • What are my treatment options?
  • How well does the treatment remove or shrink TGCT? 
  • Will treatment reduce pain and stiffness?
  • Does treatment increase range of motion?
  • What are the potential risks and/or side effects 
of treatment?
  • How will treatment fit into my daily life and activities?

Some care teams use MRI to monitor TGCT. MRIs can help to show how you are responding to surgery or prescription medications before new symptoms develop or worsen.1

Understanding treatment options

Surgery is often the primary treatment for TGCT, but it isn't right for everyone. Together, you and your care team can find a treatment plan that works for you.

Surgery

Pros2,3

  • Reduces the size of the tumor and may remove it completely, which helps with symptoms
  • It's possible that a single surgery will be all you need to remove the tumor

Cons1,4

  • Recovery can be long
  • There's a chance the tumor can come back: 72% chance with diffuse TGCT and 34% chance with localized TGCT

Prescription Medicines

Pros5

  • Target and block CSF-1, a main cause of tumor growth
  • Help with symptoms

Cons6-8

  • Patients’ tumors don’t always shrink
  • The medicine needs to be taken regularly over the long term

Things are changing in TGCT

Stay up to date on the latest developments in TGCT.

If you need more information about treatment options or have any questions, talk to your care team.

SIGN UP FOR MORE INFORMATION ON TGCT TREATMENTS

SIGN UP FOR MORE INFORMATION ON TGCT TREATMENTS

To learn about the latest insights on TGCT treatments and support to help you find the right treatment plan, sign up below. 

SIGN UP

REFERENCES

1. Stacchiotti et al. Cancer Treat Rev. 2023;112:1-10. 2. TGCT Support. Treatment. 2024. Accessed August 25, 2025. https://www.tgctsupport.org/treatment 3. Gelhorn et al. Clin Ther. 2016;38(4):778-793. 4. TGCT Support. Recovery. 2024. Accessed May 12, 2025. https://www.tgctsupport.org/recovery 5. Stern et al. Future Oncol. 2025;21(12):1501-1510. 6. ROMVIMZA Prescribing Information. Waltham, MA: Deciphera Pharmaceuticals, LLC. 7. TURALIO Prescribing Information. Basking Ridge, NJ: Daiichi Sankyo, Inc. 8. Aykan NF, Özatlı T. World J Clin Oncol. 2020;11(2):53-73.

YOU ARE NOW LEAVING TGCTWRECKS.COM

By clicking "Continue" below, you will be taken away from tgctwrecks.com to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit. You are solely responsible for your interactions with such websites.

CONTINUE TO SITE
RETURN TO TGCTWRECKS.COM
Divider desktop
Divider mobile

©2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono is a Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.

200 Pier 4 Blvd, Boston, MA 02210

This website is intended only for residents of the United States. Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

US-NONOTGCT-00008 11/25